Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by RTW Investments LP

RTW Investments LP cut its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 23.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,218,641 shares of the company's stock after selling 1,600,000 shares during the quarter. Dyne Therapeutics comprises 1.9% of RTW Investments LP's investment portfolio, making the stock its 21st biggest position. RTW Investments LP owned about 5.13% of Dyne Therapeutics worth $122,951,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DYN. Jefferies Financial Group Inc. acquired a new position in Dyne Therapeutics during the fourth quarter worth about $42,408,000. Norges Bank acquired a new position in Dyne Therapeutics during the fourth quarter worth about $22,384,000. Point72 Asset Management L.P. boosted its position in Dyne Therapeutics by 802.3% during the fourth quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company's stock worth $21,785,000 after acquiring an additional 822,201 shares during the last quarter. Braidwell LP acquired a new position in Dyne Therapeutics during the fourth quarter worth about $16,049,000. Finally, Janus Henderson Group PLC raised its stake in Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after purchasing an additional 566,146 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DYN shares. Chardan Capital reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, BMO Capital Markets started coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $46.85.

Dyne Therapeutics Stock Down 1.4%

NASDAQ DYN traded down $0.17 during trading on Monday, hitting $11.66. The stock had a trading volume of 1,581,459 shares, compared to its average volume of 1,678,854. The company has a market capitalization of $1.33 billion, a PE ratio of -3.28 and a beta of 1.19. The firm has a 50 day moving average price of $10.35 and a 200 day moving average price of $17.23. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold 6,237 shares of company stock valued at $77,760 in the last 90 days. Company insiders own 14.14% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.